(E)-eicos-9-enoic acid | 62133-71-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-eicos-9-enoic acid
• 英文别名: trans-eicosenoic acid；trans-11-C20:1；eicos-9t-enoic acid；eicos-9-enoic acid；Nonadecen-(10)-carbonsaeure-(1)；Eicos-9t-ensaeure；9t-Eicosensaeure；Eikosen-(9)-saeure-(20)；Eicos-9-ensaeure；9-Eicosenoic acid；(E)-icos-9-enoic acid
• CAS: 62133-71-5
• 化学式: C₂₀H₃₈O₂
• 分子量: 310.521
• InChiKey: LQJBNNIYVWPHFW-VAWYXSNFSA-N

物化性质

• 熔点：
  53-54 °C
• 沸点：
  402.7±14.0 °C(Predicted)
• 密度：
  0.895±0.06 g/cm3(Predicted)
• 物理描述：
  Liquid

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  22
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-eicos-9-enoic acid 生成 二十酸
  参考文献：
  名称：

  Toyama, Chemische Umschau auf dem Gebiet der Fette, Oele, Wachse und Harze, 1926, vol. 33, p. 297

  摘要：

  DOI：
• 作为产物：
  描述：

  (9Z)-9-二十碳烯酸 生成 (E)-eicos-9-enoic acid
  参考文献：
  名称：

  Toyama; Tsuchiya, The journal of the Society of Chemical Industry, Japan. Supplemental binding., 1934, vol. 37, p. 18

  摘要：

  DOI：

文献信息

• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• [EN] LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES DE PRÉGNANE ET LEURS UTILISATIONS
  申请人：PURETECH HEALTH LLC

  公开号：WO2020028787A1

  公开（公告）日：2020-02-06

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，以及其制药组合物、生产这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所述的脂质前药或其制药组合物。
• BIOPASSIVATING MEMBRANE STABILIZATION BY MEANS OF NITROCARBOXYLIC ACID-CONTAINING PHOSPHOLIPIDS IN PREPARATIONS AND COATINGS
  申请人：Dietz Ulrich

  公开号：US20140099354A1

  公开（公告）日：2014-04-10

  The present invention relates to nitro-carboxylic acid (s)-containing phospholipids, to be used for coating of medical devices such as stents, catheter balloons, wound pads or surgical suture material and for bio-passivating compositions, such as rinses, waterproofing solutions, coating solutions, cryoprotection solutions, cold preservation media, lyoprotection solutions, contrast media solutions, preservation and reperfusion solutions containing these compounds as well as preparing solutions thereof and coating medical devices as well as their uses.

  本发明涉及一种含硝基羧酸（s）的磷脂，用于涂覆医疗器械，如支架、导管球囊、伤口垫或外科缝合材料，以及用于生物钝化组合物，如漱口液、防水溶液、涂层溶液、冷冻保护溶液、冷藏介质、冻干保护溶液、造影介质溶液、含有这些化合物的保存和再灌注溶液，以及制备这些溶液和涂覆医疗器械以及它们的用途。
• METHOD FOR THE SYNTHESIS OF OMEGA-AMINO-ALKANOIC ACIDS
  申请人：Dubois Jean-Luc

  公开号：US20100168453A1

  公开（公告）日：2010-07-01

  The invention relates to a method for the synthesis of amino acids/esters of general formula NH 2 —(CH 2 ) n —COOR in which n is an integer between 5 and 14, and R is either H or an alkyl radical including from 1 to 4 carbon atoms, from natural long-chain mono-unsaturated fatty acids or esters including at least 10 adjacent carbon atoms per molecule, said method comprising: first converting, if necessary, said natural long-chain fatty acid or ester into a monounsaturated fatty acid/ester of general formula R 1 —(CH 2 ) m —CH═CH—(CH 2 ) p —COOR in which R 1 is H, CH 3 or a COOR radical, m is an integer between 0 and 14 and p is an integer between 2 and 11, then submitting the latter to a crossed catalytic metathesis reaction with a compound of formula R 2 —CH═CH—R 3 in which R 2 is either H or CN and R 3 is CN or CH 2 NH 2 , provided that if R 2 is CN, R 3 can be only CN, and finally converting the resulting product of the general formula R 3 —CH═CH—(CH 2 ) p —COOR into an amino-acid, either by hydrogenation, or by hydrogenation of the triple terminal bond, or by amination of the double terminal bond.

  本发明涉及一种合成通式为NH2—(CH2)n—COOR的氨基酸/酯的方法，其中n为5至14之间的整数，R为H或包括1至4个碳原子的烷基基团，所述方法包括：首先，如果必要，将天然长链脂肪酸或酯转化为通式为R1—(CH2)m—CH═CH—(CH2)p—COOR的单不饱和脂肪酸/酯，其中R1为H，CH3或COOR基团，m为0至14之间的整数，p为2至11之间的整数；然后，将后者与通式为R2—CH═CH—R3的化合物进行交叉催化复分解反应，其中R2为H或CN，R3为CN或CH2NH2，如果R2为CN，则R3只能为CN；最后，将得到的通式为R3—CH═CH—(CH2)p—COOR的产品转化为氨基酸，可以通过氢化，或通过氢化末端的三键，或通过末端的双键的氨基化来实现。
• [EN] LIPID PRODRUGS OF NEUROSTEROIDS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES
  申请人：PURETECH LYT INC

  公开号：WO2021159021A1

  公开（公告）日：2021-08-12

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统导向的脂质前药、其药物组合物、制备此类前药和组合物的方法，以及提高包含在脂质前药中的治疗剂的生物利用度或其他特性的方法。本发明还提供了治疗如本文所述的疾病、紊乱或状况的方法，包括向有需要的患者施用所述的脂质前药或其药物组合物。